Nizatidine (CAS 76963-41-2) is a well-established pharmaceutical compound primarily known for its efficacy as a histamine H2 receptor antagonist. For researchers and product formulators, a deep understanding of its properties and applications is crucial for successful drug development and manufacturing.

Chemically, Nizatidine is characterized by its specific molecular structure which contributes to its pharmacological activity. It presents as a white to off-white crystalline powder, with a high purity level often exceeding 99.5%. Its molecular formula is C12H21N5O2S2, and it possesses a molecular weight of approximately 331.46 g/mol. Key physical properties include a melting point typically between 130-132°C. Its solubility characteristics, being sparingly soluble in water but soluble in methanol, are important considerations for formulation scientists.

The primary therapeutic application of Nizatidine lies in its ability to inhibit gastric acid secretion. This action makes it highly effective in treating conditions associated with excessive stomach acid, such as:

  • Active duodenal ulcers
  • Benign gastric ulcers
  • Prevention of recurrence after duodenal ulcer healing
  • Gastroesophageal reflux disease (GERD)

As an H2 receptor antagonist, Nizatidine works by competitively inhibiting the binding of histamine to H2 receptors on gastric parietal cells, thereby reducing the production of stomach acid. This mechanism is fundamental to its antiulcer and anti-reflux properties.

For R&D scientists, Nizatidine serves as a vital compound for further research into gastrointestinal pharmacology and the development of novel therapeutics. For product formulators, understanding its solubility and stability is key to creating effective dosage forms. When you buy Nizatidine for research or manufacturing, ensuring its quality and purity from a reputable Nizatidine manufacturer is paramount. Sourcing from experienced suppliers guarantees that you receive a product meeting stringent quality controls, essential for its intended pharmaceutical applications.